scholarly journals The efficacy of mycophenolate mofetil in treating Takayasu arteritis: a systematic review and meta-analysis

2017 ◽  
Vol 37 (7) ◽  
pp. 1083-1088 ◽  
Author(s):  
Danping Dai ◽  
YangYang Wang ◽  
Haiying Jin ◽  
Yiyang Mao ◽  
Hao Sun
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Takayasu Arteritis ◽  
Meta Analysis

scholarly journals Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis—a systematic review and meta-analysis

2021 ◽  
Author(s):  
Durga Prasanna Misra ◽  
Upendra Rathore ◽  
Pallavi Patro ◽  
Vikas Agarwal ◽  
Aman Sharma
Keyword(s):  
Systematic Review ◽  
Takayasu Arteritis ◽  
Meta Analysis ◽  
Disease Modifying

scholarly journals Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis

BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e040371
Author(s):  
Mengyu Han ◽  
Luqi Nong ◽  
Ziqiang Liu ◽  
You Chen ◽  
Yang Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Neuromyelitis Optica ◽  
Meta Analysis ◽  
Grey Literature ◽  
Relevant Literature ◽  
Biomedical Literature ◽  
Cochrane Library ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Spectrum Disorders

IntroductionNeuromyelitis optica spectrum disorders (NMOSD) is an inflammatory and heterogeneous astrocyte disorder of the central nervous system with the characteristic of higher incidence in women and Asian people. Most patients with NMOSD have a course of recurrence and remission that is prone to cause paralysis and blindness. Several studies have confirmed the efficacy and promising prospect of mycophenolate mofetil (MMF) in the treatment of NMOSD. Yet its therapeutic effect and safety are controversial. Although there has been two published literature that is relevant to the topic of this study, both of them have certain defects, and they can only provide answers about the efficacy or safety of MMF in the treatment of NMOSD from partial perspectives or conclusions. This research aims to perform a direct and comprehensive systematic review and meta-analysis to evaluate MMF’s effectiveness and safety in treating NMOSD.Methods and analysisThis systematic review will cover all comparative researches, from randomised controlled trials to cohort studies, and case–control study. A relevant literature search will be conducted in PubMed, Web of Science, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database and Chinese Biomedical Literature Database from their inception to 31 June 2020. We will also search registers of clinical trials, potential grey literature and abstracts from conferences. There are no limits on language and publication status. The reporting quality and risk of bias will be assessed by two researchers independently. Expanded Disability Status Scales and annualised relapse rate will be evaluated as the primary outcome. The secondary outcomes will consist of the frequency and severity of adverse events, best-corrected visual acuity, relapse-free rate and time to the next attack. A meta-analysis will be performed using RevMan V.5.3 software provided by the Cochrane Collaboration and Stata V.12.0.Ethics and disseminationBecause the data used for this systematic review will be exclusively extracted from published studies, ethical approval and informed consent of patients will not be required. The systematic review will be published in a peer-reviewed journal, presented at conferences and will be shared on social media platforms.PROSPERO registration numberCRD42020164179.

scholarly journals Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis

2007 ◽  
Vol 2 (5) ◽  
pp. 968-975 ◽  
Author(s):  
Michael Walsh ◽  
Matthew James ◽  
David Jayne ◽  
Marcello Tonelli ◽  
Braden J. Manns ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Induction Therapy ◽  
Meta Analysis

scholarly journals Efficacy and Safety of Mycophenolate Mofetil Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Sakdipat Songwisit ◽  
Punchika Kosiyakul ◽  
Jiraporn Jitprapaikulsan ◽  
Naraporn Prayoonwiwat ◽  
Patompong Ungprasert ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Disease Severity ◽  
Relapse Rate ◽  
Neuromyelitis Optica ◽  
Meta Analysis ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Efficacy And Safety ◽  
Number Of Patients ◽  
Spectrum Disorders

Abstract Background: Neuromyelitis optica spectrum disorders (NMOSD) is an autoimmune demyelinating disease of the central nervous system characterized by severe attacks of optic nerve and spinal cord. Mycophenolate mofetil (MMF) is an immunosuppressive agent (IS) which is widely prescribed for NMOSD patients. This systematic review and meta-analysis aims to assess the efficacy and safety of MMF in controlling relapse and disease severity.Methods: Studies were obtained from the EMBASE and Ovid MEDLINE databases. Eligible studies were the studies of NMOSD patients treated with MMF which reported treatment outcomes as Annualized Relapse Rate (ARR) or Expanded Disability Status Scale (EDSS) before and after treatment. Case reports, case series less than 3 patients, and reviews were excluded.Results: Fifteen studies included 1047 patients, of whom 915 (87.4%) were aquaporin-4 immunoglobulin seropositive. The total number of patients that received MMF was 799. Meta-analysis on ARR and EDSS were conducted in 4 studies with a total of 200 patients and 3 studies with a total of 158 patients, respectively. The result showed a significant improvement with a mean reduction of 1.13 (95% confidence interval (CI), 0.60 to 1.65) in ARR and a mean reduction of 0.85 (95% CI, 0.36 to 1.34) in EDSS after MMF therapy. Adverse drug reactions occurred in 106 (17.8%) of 594 patients that were documented having side effects during MMF therapy.Conclusion: This systematic review and meta-analysis showed that using MMF as a preventive therapy in NMOSD patients can significantly reduce relapse rate and improve disease severity with an acceptable tolerability.

Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease – Systematic review and meta-analysis

2014 ◽  
Vol 38 (3) ◽  
pp. 352-360 ◽  
Author(s):  
Ron Ram ◽  
Moshe Yeshurun ◽  
Liat Vidal ◽  
Ofer Shpilberg ◽  
Anat Gafter-Gvili
Keyword(s):  
Systematic Review ◽  
Mycophenolate Mofetil ◽  
Graft Versus Host Disease ◽  
Meta Analysis ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Takayasu Arteritis: a Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

2021 ◽  
Vol 3 (2) ◽  
pp. 80-90
Author(s):  
Anisha B. Dua ◽  
Mohamad A. Kalot ◽  
Nedaa M. Husainat ◽  
Kevin Byram ◽  
Jason M. Springer ◽  
...  
Keyword(s):  
Systematic Review ◽  
Takayasu Arteritis ◽  
Meta Analysis ◽  
Test Accuracy
Sign in / Sign up

Export Citation Format

Share Document